INVESTMENT IN COMPEDICA (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
Mar. 31, 2026	Feb. 06, 2026	Jun. 05, 2025
Notes and other explanatory information [abstract]
reimbursement of expenses			$ 100
Loss on impairment	$ 4,800
Change in fair value on the investment in Compedica		$ 200

The amount expected to be reimbursed by another party on expenditures to settle other provisions. [Refer: Other provisions]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 37
-IssueDate 2025-01-01
-Paragraph 85
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_85_c&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 258
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_258_c&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 258
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_258_c&doctype=Standard
-URIDate 2025-03-27

Name:	ifrs-full_ExpectedReimbursementOtherProvisions
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant